Pacific Biosciences
PACB
263 hedge funds and large institutions have $5.47B invested in Pacific Biosciences in 2021 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 80 increasing their positions, 78 reducing their positions, and 27 closing their positions.
204% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 27
137% more call options, than puts
Call options by funds: $70.1M | Put options by funds: $29.6M
25% more funds holding
Funds holding: 210 → 263 (+53)
24% more capital invested
Capital invested by funds: $4.42B → $5.47B (+$1.05B)
3% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 78
5.86% less ownership
Funds ownership: 90.98% → 85.12% (-5.9%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$121M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$104M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$53.7M |
| 4 |
Two Sigma Investments
New York
|
+$49.5M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$48.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$252M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$72M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$65.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$54.5M |
| 5 |
BAMCO Inc
New York
|
-$52.9M |
PACB Hedge Fund Activity: Q1 2021 in Review
263 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2021, worth a combined $5.47B — up 24% from $4.42B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new PACB positions and 27 closed out — a net gain of 55 holders — while 80 added to existing stakes and 78 trimmed.
The largest buyer was Vanguard Group, adding an estimated $121M. The largest seller was ARK Investment Management, cutting an estimated $252M.
- 263 institutional investors held Pacific Biosciences (PACB) as of Q1 2021, up from 210 in Q4 2020.
- Funds reported $5.47B of Pacific Biosciences stock for Q1 2021, up 24% quarter-over-quarter.
- 82 funds opened new Pacific Biosciences positions in Q1 2021 and 27 closed out, a net change of +55 holders.
- The largest Pacific Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $121M added.
- The largest Pacific Biosciences seller in Q1 2021 was ARK Investment Management, an estimated $252M sold.
Based on aggregated 13F filings for Q1 2021.